SARPS - Journal of Advanced Research in Plant Science
July-September 2026 2(2)
https://journalofplantscience.com

Original Article

BIOACTIVE MOLECULES FROM MEDICINAL AND AROMATIC PLANTS FOR HEART HEALTH

Sima Mandal [1*]
[1] Ph.D Assistant Professor, Department of Botany, Raniganj girls' College, Raniganj, Searsole, Rajbari, Dist- Paschim Bardhaman, State- West Bengal, India

ABSTRACT

Heart disease keeps a grip on things, like the worlds biggest killer, and that grim reality has sort of pushed scientists and regular people back toward something old school: plants. This article kinda looks at how bioactive molecules in medicinal and aromatic plants might support cardiovascular health, drawing from peer-reviewed clinical trials and also broader global health data. Cardiovascular diseases caused an estimated 19.8 million deaths worldwide in 2022, according to the World Health Organization, and that makes prevention feel more urgent than ever. Compounds like allicin from garlic, curcumin from turmeric, flavonoids from hawthorn, and resveratrol from grapes have each been examined in randomized controlled trials for possible effects on blood pressure, cholesterol, and the performance of blood vessels. Garlic extract for instance has shown measurable reductions in systolic blood pressure among hypertensive patients, while hawthorn extract has supported better exercise endurance in people living with chronic heart failure. Curcumin seems to help the inner lining of blood vessels, improving what researchers call flow mediated dilation. The article also moves through the biological mechanisms behind these effects, including antioxidant activity, anti-inflammatory signaling, and lipid regulation, and it provides a comparative table that summarizes clinical findings for the main compounds discussed. It even gets into the practical details: dosage ranges used in trials, safety concerns, drug interactions, and the gap between promising lab results and real-world clinical guidance. While the evidence is encouraging, it is not a substitute for conventional cardiology care, and the piece is honest about where the research still comes up short.

Keywords: Medicinal Plants, Allicin, Curcumin, Phytotherapy, Bioactive Molecules, Cardiovascular Health

INTRODUCTION

BACKGROUND

Walk into almost any kitchen in South Asia, the Mediterranean or Latin America, and you'll find garlic, turmeric, cinnamon, or rosemary sitting within arm's reach. These plants have flavored food for thousands of years, yet long before anyone understood biochemistry, people also used them as medicine. Grandmothers pressed garlic paste right onto wounds. Turmeric milk became the default fix for almost anything. Nobody back then really talked about allicin or curcumin, but they still were reaping the benefits anyway.

Modern science has slowly caught up with that old folk idea. Over the past three decades, researchers have separated and examined the specific molecules behind those effects, and many of them seem to have real, measurable value for the heart and blood

*Corresponding Author:
Email address: Sima Mandal (simamandal@ymail.com)

Received: 26 July 2026; **Accepted:** 12 August 2026; **Published** 04 September 2026
DOI: 10.29121/SARPS.v2.i2.2026.39
Page Number: 40-46
Journal Title: SARPS - Journal of Advanced Research in Plant Science
Journal Abbreviation: SARPS- J. Adv. Res. Plant Sci.
Online ISSN: 3108-2521, **Print ISSN:** 3139-3004
Publisher: Granthaalayah Publications and Printers, India
Conflict of Interests: The authors declare that they have no competing interests.
Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Authors' Contributions: Each author made an equal contribution to the conception and design of the study. All authors have reviewed and approved the final version of the manuscript for publication.
Transparency: The authors affirm that this manuscript presents an honest, accurate, and transparent account of the study. All essential aspects have been included, and any deviations from the original study plan have been clearly explained. The writing process strictly adhered to established ethical standards.

vessels. This isn't some fringe notion anymore. Big journals now publish meta-analyses on garlic and blood pressure, curcumin and endothelial function, hawthorn and heart failure symptoms, with the same careful standards used for pharmaceutical drugs.

WHY LOOK TO PLANTS FOR HEART HEALTH

Heart disease does not really care about geography or income, even if it does seem to "pick" who gets treated, especially when access to care is limited. Statins, beta blockers, and ACE inhibitors save lives every single day, and this article doesn't try to say anything different. But millions of people around the world, mainly in low- and middle-income countries, still lean on traditional plant-based remedies as their first step, or sometimes their only step. Figuring out which of those remedies actually do something, and in what way, is huge for public health.

There's also this steady rising curiosity from people who are already on standard treatment, but who want to tack on "just one more" thing, a bit of extra support that could lower risk, perhaps modestly, without big side effects. That's basically why this subject needs a straight forward, honest look, with real data, not just wishful thinking.

THE CARDIOVASCULAR DISEASE BURDEN AND THE CASE FOR PHYTOTHERAPY
A GLOBAL HEALTH EMERGENCY

Cardiovascular diseases remain, by a wide margin the leading cause of death on the planet, it's pretty hard to ignore. An estimated 19.8 million people died from cardiovascular diseases in 2022, this is roughly 32% of all global deaths, and about 85% of those deaths were due to heart attack and stroke. It's not a small statistic to sit with, you know? It kind of means one in three deaths worldwide is connected to a heart or blood vessel problem, in some way.

What makes it even more sobering is where the burden lands hardest. More than three quarters of cardiovascular disease deaths happen in low- and middle-income countries, places where costly cardiac interventions are often out of reach for ordinary families. A broader set of figures from the World Heart Federation shows cardiovascular disease deaths increased globally from 12.1 million in 1990 to 20.5 million in 2021, and about four in five of those deaths occurred in low- and middle-income countries too. Population growth and aging explain part of the rise, because the age-standardized death rate actually went down from 354.5 per 100,000 people in 1990 to 239.9 per 100,000 in 2019. And still, the sheer scale of suffering keeps growing, no matter what you try to compare.

A separate large-scale analysis of global disease burden found that elevated LDL cholesterol alone was linked to an estimated 3.81 million cardiovascular deaths in 2021, underlining how much of this burden connects directly to something diet and lifestyle can influence.

Figure 1



Figure 1 Global Cardiovascular Disease Mortality Trend, 1990–2022

This line chart kinda shows the increase in global cardiovascular disease deaths, starting at 12.1 million in 1990 and going up to 19.8 million in 2022, and then there is another line that declines, it indicates how the age standardized death rate drops from 354.5 down to 239.9 deaths per 100,000 people, across the 1990 to 2019 span. In other words the figure makes it clear that total deaths

moved higher because population growth and aging are pushing the numbers, yet the real risk for each person is going down—mostly due to improved prevention and treatment options. Data came from the World Health Organization. (2021) fact sheet on cardiovascular diseases and the World Heart Federation's World Heart Federation. (2023).

TRADITIONAL MEDICINE GETS A SEAT AT THE TABLE

The World Health Organization has not just ignored this reality, it sort of keeps saying the same thing in different ways. In its own traditional medicine strategy, it openly acknowledges that a huge share of the global population depends on herbal and traditional remedies for primary healthcare, and it has pushed member states to evaluate these practices scientifically, rather than shrug them off outright. And yeah that shift really matters. It moves plant based cardiovascular support out of the realm of anecdote and into testable, falsifiable science, which is exactly where it belongs, or at least where it should be.

KEY BIOACTIVE MOLECULES AND THEIR CARDIOVASCULAR EFFECTS

ALLICIN AND ORGANOSULFUR COMPOUNDS FROM GARLIC (ALLIUM SATIVUM)

Garlic is probably one of the most studied medicinal plants for heart health, and honestly for good reason. When you crush a garlic clove, an enzyme called alliinase turns a compound known as alliin into allicin. That sulfur-heavy molecule is what gives garlic its sharp smell, and it also seems to drive a lot of the biological action people talk about.

The blood pressure story is genuinely strong. A systematic review and meta-analysis of eleven trials found that garlic led to an average drop of 4.6 mm Hg in systolic blood pressure versus placebo. In the hypertensive subgroup, the effect was even larger, with systolic pressure falling by 8.4 mm Hg and diastolic pressure dropping by 7.3 mm Hg. This isn't a tiny change. As a bit of context, some blood pressure medications tend to reduce numbers in a comparable ballpark. Another meta-analysis, which included trials up to 2013, basically confirmed the same pattern. It reported that garlic intake was linked to a 3.75 mm Hg decline in systolic blood pressure and a 3.39 mm Hg decline in diastolic blood pressure. In hypertensive people, systolic reductions were more noticeable, reaching 4.4 mm Hg.

And garlic's advantages don't really stop there. In people dealing with type 2 diabetes which is tightly knotted with cardiovascular risk garlic supplementation over 24 weeks led to a meaningful drop in fasting blood glucose, and also to improvements in cholesterol and the high-density lipoprotein levels. There's also research in liver disease patients that felt more targeted. In that group, 400 mg of garlic powder each day for 15 weeks reduced systolic blood pressure by close to 8 mm Hg, and diastolic pressure by more than 5 mm Hg compared to placebo. Along the way, C reactive protein, the inflammatory marker, also went down in a noticeable way.

CURCUMIN FROM TURMERIC (CURCUMA LONGA)

Turmeric's golden hue is mostly curcumin at work, a polyphenol that has kind of turned into a nutrition-science celeb, sometimes for good reasons and sometimes just because of overly loud, marketing hype. But on the cardiovascular angle, the evidence actually stays pretty solid, at least for the main outcomes people look at.

In one meta-analysis of ten studies, researchers checked how curcumin change's endothelial function, basically how efficiently blood vessels relax and react to circulation. They saw a significant rise in flow-mediated dilation after supplementation. That's not a tiny detail because weaker flow-mediated dilation can be an early nudge, like a first alarm for blood vessel strain or damage, way before things like a heart attack or stroke appear clearly on later scans.

Then a newer dose-response style analysis went further, pairing blood pressure outcomes with vascular markers, and it reported better flow-mediated dilation, with a weighted mean difference of 2.00%. In that same review they also found improvements for blood pressure, but they didn't see a steady effect on some inflammatory adhesion molecules. So the takeaway is sort of nuanced: curcumin's effects seem genuine, yet they're not guaranteed to show up across all single marker researchers try to measure, not every time either.

FLAVONOIDS AND OLIGOMERIC PROCYANIDINS FROM HAWTHORN (CRATAEGUS SPP.)

Hawthorn kind of deserves more attention than it normally gets outside cardiology circles, even if most people never really hear about it. It's made from dried leaves flowers and berries from the hawthorn shrub, and it has actually been approved in Germany as a prescription option for mild heart failure, which tells you something about how seriously European regulators treat the evidence.

There's a landmark meta-analysis that pooled eight clinical trials, involving 632 patients with chronic heart failure, and the results suggest that hawthorn extract noticeably increased maximal workload compared to placebo, with a weighted mean difference around 7 watts. Sure, that can sound a little modest on paper, but for someone whose symptoms restrict basic day to day movement, having the ability to push a bit more before becoming breathless is a very tangible quality-of-life tweak.

Then later there was a Cochrane review that went further, looking at fourteen double-blind, placebo-controlled trials. It reported improvements in heart failure symptoms and heart function in the trials that were suitable for pooled analysis. Also, it's important to be straight about the uncertainty: not every trial matched the pattern. The HERB-CHF trial, which was randomized and well-designed, found no significant benefit versus placebo, and the researchers pointed out that hawthorn's effects look steadier in milder heart failure, rather than in more advanced cases.

RESVERATROL FROM GRAPES AND OTHER PLANT SOURCES

Resveratrol got really well known because of the so-called French paradox, that odd observation where French groups seemed to show lower rates of coronary heart disease even though their diets had a lot of saturated fat. At first, researchers figured that every day, moderate red wine might explain a slice of that difference, and they pointed toward resveratrol plus related polyphenols in grape skins as the likely driver or mechanism, somehow.

After that, resveratrol started being looked at more steadily, especially for what it does to lipid profiles and blood vessel wellbeing. A lot of reviews talk about believable antioxidant and anti-inflammatory routes, things that could reasonably shield blood vessels across time. Still, resveratrol stays one of the more debated compounds in this area, partly since human trials often rely on amounts that are much higher than what a person would actually take in from food, or from wine, so turning lab results into dietary guidance really needs to be handled with care.

AROMATIC PLANT COMPOUNDS: CINNAMON, ROSEMARY, AND ESSENTIAL OIL CONSTITUENTS

Aromatic plants bring along a sort of different batch of bioactive molecules, mostly the kind that are volatile, like those found in essential oils. Cinnamaldehyde from cinnamon and rosmarinic acid from rosemary both have shown antioxidant effects in lab studies, and in a few smaller human trials there are hints of modest improvements in lipid markers too, especially in people with metabolic syndrome. The overall evidence is a bit thinner than what we see for garlic or hawthorn, mainly because there are fewer big, large scale randomized trials, but the mechanistic narrative, lowering oxidative stress and easing that low grade inflammation, kind of fits well with what we understand about how atherosclerosis develops.

MECHANISMS BEHIND CARDIOPROTECTION

ANTIOXIDANT AND ANTI-INFLAMMATORY PATHWAYS

Almost every plant compound discussed here seems to have some kind of common thread, they help to neutralize reactive oxygen species, and at the same time dial down inflammatory signaling a bit too. Oxidized LDL cholesterol is a big mover when it comes to plaque buildup inside arteries, and compounds like curcumin and allicin look like they interfere with this oxidation process on a molecular level. Chronic low-grade inflammation meanwhile keeps blood vessel walls in this ongoing state of irritation, so they become more likely to rupture plaques. Reducing inflammatory markers such as C-reactive protein, as garlic has been shown to do, kind of chips away at that inflammatory background noise.

LIPID PROFILE MODULATION

A bunch of these compounds nudge cholesterol levels in a favorable direction, but honestly the effect size vary quite a lot between different studies, so it's a bit all over the place. With garlic, the impact on LDL and total cholesterol usually stays modest, though it still looks pretty steady across trials. Curcumin on the other hand seems more unpredictable, its lipid effects depend on dose and also on the exact formulation, so you can't really generalize it cleanly. Still, none of these comes anywhere near replacing statins for raw cholesterol lowering power, and no one who's serious in the field really says otherwise. They tend to work better as an add-on rather than a substitute, at least in practical terms.

ENDOTHELIAL AND VASCULAR EFFECTS

Honestly the most exciting mechanism, at least from research stand point, kind of involves the endothelium, that thin layer of cells that lines nearly every blood vessel. When it's healthy the endothelium produces nitric oxide, and that relaxes the vessels, so blood pressure stays more or less under control. Curcumin's effect on flow mediated dilation probably works by nudging nitric oxide availability higher, but hawthorn's positive inotropic effects, meaning it strengthens the force behind heart muscle contraction, seems to go through a related yet still distinct route, mostly tied to calcium handling in the heart cells.

Figure 2



Figure 2 Mechanistic Pathways Linking Plant Bioactive Compounds to Cardiovascular Protection

This conceptual flow chart kinda maps four major bioactive compounds, allicin curcumin hawthorn flavonoids and resveratrol, to their main physiological targets like oxidative stress reduction, inflammatory marker suppression, endothelial nitric oxide signaling, and lipid metabolism. Arrows then connect each compound to the downstream cardiovascular outcome it influences most directly, such as blood pressure reduction or improved flow mediated dilation. The diagram sort of pulls from mechanistic findings summarized in Gupta et al. (2013) and Tabrizi et al. (2019), so it reads like even though these compounds share overlapping antioxidant virtues, each one still tends to lean toward a slightly different primary mechanism of action.

COMPARATIVE CLINICAL EVIDENCE

The table below pulls together the clinical findings discussed so far, giving a side-by-side view of what the strongest available trials actually measured.\

Bioactive Compound	Plant Source	Primary Cardiovascular Effect	Key Clinical Finding	Source
Allicin	Garlic (Allium sativum)	Blood pressure reduction	Systolic BP reduced by 8.4 mmHg in hypertensive patients	Ried et al. (2008)
Allicin	Garlic (Allium sativum)	Glycemic and lipid control	Improved fasting glucose and cholesterol over 24 weeks in T2DM patients	Wang et al. (2017)
Curcumin	Turmeric (Curcuma longa)	Endothelial function	Significant increase in flow-mediated dilation (WMD: 1.49%)	Tabrizi et al. (2019)
Curcumin	Turmeric (Curcuma longa)	Blood pressure and vascular markers	Flow-mediated dilation improved by 2.00%	Dehzad et al. (2024)
Oligomeric procyanidins/flavonoids	Hawthorn (Crataegus spp.)	Exercise capacity in heart failure	Maximal workload increased by 7 watts across 632 patients	Pittler et al. (2003)
Oligomeric procyanidins/flavonoids	Hawthorn (Crataegus spp.)	Heart failure symptoms	Improved symptoms and cardiac function in pooled trials	Pittler et al. (2008)

SAFETY, DOSAGE, AND PRACTICAL CONSIDERATIONS

None of this is some kind of free pass to self-medicate without talking to a doctor. Garlic trials have generally used doses around 600 mg to 1,200 mg of a standardized extract per day, though garlic can also thin the blood, so if someone is already using anticoagulant medication, they really need to be careful, and they should mention garlic supplements to their physician before

surgery or procedures. Hawthorn trials used doses roughly 160 mg up to 1,800 mg daily, and even if side effects were mostly mild, nausea and dizziness did show up now and then, plus it can, at least theoretically interact with heart meds like digoxin. Curcumin's main practical snag usually isn't safety, it's how the body takes it in. Curcumin on its own isn't absorbed very well, so many trials rely on enhanced formulations that pair it with piperine from black pepper, or use lipid-based delivery systems. The honest takeaway is that these compounds tend to work best when they're folded into a wider lifestyle plan, along with a heart-healthy eating pattern, regular movement, and not smoking, instead of being treated as a standalone fix.

CHALLENGES AND FUTURE DIRECTIONS

The research gap that keeps showing up over and over is this thing about standardization, like honestly its hard to get past. You look at two garlic supplements sitting on the pharmacy shelf and they can have wildly different allicin levels depending on how theyre processed, and it's pretty similar with curcumin extracts too. That kind of inconsistency makes it genuinely tough to compare findings from different trials, or to offer a steady dosage suggestion with confidence, because the baseline just isnt the same. What would really help close the gap would be bigger longer studies using standardized extracts, not just smaller ones that vary from batch to batch. There's also a clear need for more work on how these compounds interact with everyday cardiovascular drugs, since more and more patients take both at the same time, and their doctors may not always know about the herbal side of things.

CONCLUSION

Medicinal and aromatic plants are not some miracle fix for heart disease, and treating them like they do everything is kind of dishonest. Still, the evidence collected over the past few decades suggests they are also not nothing, either. Garlic has blood pressure effects that can line up with certain pharmaceutical results in people who are hypertensive. Hawthorn genuinely lets some folks with heart failure go a little farther before they run out of breath. Curcumin nudges the inner lining of blood vessels toward better function in ways that actually matter for long term cardiovascular risk. That's not folklore dressed up in scientific words, these are real, measurable, peer-reviewed findings.

At the same time, cardiovascular disease is still the world's leading killer, taking close to 20 million lives each year, and no amount of turmeric or garlic will, by itself, reverse that trend. What this plant compounds seem to offer is more like a complementary layer of defense, the kind that sits alongside statins, blood pressure medications, and lifestyle change rather than replacing them. In low-resource settings where pharmaceutical access is spotty, this extra layer can matter an awful lot.

Looking ahead, the research needs more standardized extracts, longer trials, and clearer dosing instructions before these compounds can be woven confidently into mainstream clinical protocols. Until then, the honest stance is cautious optimism. These plants do carry real pharmacological weight, supported by real data, and they deserve a continued spot in serious cardiovascular research, not being pushed aside as old wives tales or marketed as miracle cures. Somewhere between those two extremes is the real truth, and honestly, it feels encouraging.

ACKNOWLEDGMENTS

None.

REFERENCES

Bonnefont-Rousselot, D. (2016). Resveratrol and Cardiovascular Diseases. Nutrients, 8(5), 250. https://doi.org/10.3390/nu8050250

Dehzad, M. J., Ghalandari, H., and Askarpour, M. (2024). Curcumin/Turmeric Supplementation Could Improve Blood Pressure and Endothelial Function: A Grade-Assessed Systematic Review and Dose–Response Meta-Analysis of Randomized Controlled Trials. Clinical Nutrition ESPEN, 59, 194–207. https://doi.org/10.1016/j.clnesp.2023.11.020

Food and Agriculture Organization of the United Nations. (2005). Trade in Medicinal Plants. FAO.

Gupta, S. C., Patchva, S., and Aggarwal, B. B. (2013). Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials. The AAPS Journal, 15(1), 195–218. https://doi.org/10.1208/s12248-012-9432-8

Hooper, L., Kroon, P. A., Rimm, E. B., Cohn, J. S., Harvey, I., Le Cornu, K. A., Ryder, J. J., Hall, W. L., and Cassidy, A. (2008). Flavonoids, Flavonoid-Rich Foods, and Cardiovascular Risk: A Meta-Analysis of Randomized Controlled Trials. The American Journal of Clinical Nutrition, 88(1), 38–50. https://doi.org/10.1093/ajcn/88.1.38

Panahi, Y., Khalili, N., Sahebi, E., Namazi, S., Karimian, M. S., Majeed, M., and Sahebkar, A. (2016). Curcuminoids Modify Lipid Profile in type 2 Diabetes Mellitus: A Randomized Controlled Trial. Complementary Therapies in Medicine, 33, 1–5. https://doi.org/10.1016/j.ctim.2017.05.006

Pittler, M. H., Guo, R., and Ernst, E. (2008). Hawthorn Extract for Treating Chronic Heart Failure. Cochrane Database of Systematic Reviews, (1), CD005312. https://doi.org/10.1002/14651858.CD005312.pub2

Pittler, M. H., Schmidt, K., and Ernst, E. (2003). Hawthorn Extract for Treating Chronic Heart Failure: Meta-Analysis of Randomized Trials. The American Journal of Medicine, 114(8), 665–674. https://doi.org/10.1016/S0002-9343(03)00131-1

Renaud, S., and de Lorgeril, M. (1992). Wine, Alcohol, Platelets, and the French Paradox for Coronary Heart Disease. The Lancet, 339(8808), 1523–1526. https://doi.org/10.1016/0140-6736(92)91277-F

Ried, K., Frank, O. R., Stocks, N. P., Fakler, P., and Sullivan, T. (2008). Effect of Garlic on Blood Pressure: A Systematic Review and Meta-Analysis. BMC Cardiovascular Disorders, 8, 13. https://doi.org/10.1186/1471-2261-8-13

Ried, K., and Fakler, P. (2014). Potential of garlic (Allium sativum) in Lowering High Blood Pressure: Mechanisms of Action and Clinical Relevance. Integrated Blood Pressure Control, 7, 71–82. https://doi.org/10.2147/IBPC.S51434

Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., Bonny, A., Brauer, M., Brodmann, M., Cahill, T. J., Carapetis, J., Catapano, A. L., Chugh, S. S., Cooper, L. T., Coresh, J., … Fuster, V. (2020). Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update from the GBD 2019 Study. Journal of the American College of Cardiology, 76(25), 2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010

Sahebkar, A. (2013). Effects of Resveratrol Supplementation on Plasma Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrition Reviews, 71(12), 822–835. https://doi.org/10.1111/nure.12081

Tabrizi, R., Vakili, S., Lankarani, K. B., Akbari, M., Mirhosseini, N., Ghayour-Mobarhan, M., and Asemi, Z. (2019). The Effects of Curcumin Supplementation on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Phytotherapy Research, 33(2), 296–307. https://doi.org/10.1002/ptr.6226

Wang, J., Zhang, X., Lan, H., and Wang, W. (2017). Effect of Garlic Supplement in the Management of Type 2 Diabetes Mellitus (T2DM): A Meta-Analysis of Randomized Controlled trials. Food & Nutrition Research, 61(1), 1377571. https://doi.org/10.1080/16546628.2017.1377571

World Health Organization. (2013). WHO Traditional Medicine Strategy 2014–2023. World Health Organization.

World Health Organization. (2021). Cardiovascular Diseases (CVDs) [Fact sheet]. World Health Organization.

World Heart Federation. (2023). World Heart Report 2023: Confronting the world's Number One Killer. World Heart Federation.

Xiong, X. J., Wang, P. Q., Li, S. J., Li, X. K., Zhang, Y. Q., and Wang, J. (2015). Garlic for Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Phytomedicine, 22(3), 352–361. https://doi.org/10.1016/j.phymed.2014.12.013

Zick, S. M., Vautaw, B. M., Gillespie, B., and Aaronson, K. D. (2009). Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial. European Journal of Heart Failure, 11(10), 990–999. https://doi.org/10.1093/eurjhf/hfp116